RS20050461A - Primena kombinacije koja obuhvata inhibitor nenukleotidne reverzne transkriptaze (nnrti) sa inhibitorom citohroma p450, kao što su inhibitori proteaze - Google Patents

Primena kombinacije koja obuhvata inhibitor nenukleotidne reverzne transkriptaze (nnrti) sa inhibitorom citohroma p450, kao što su inhibitori proteaze

Info

Publication number
RS20050461A
RS20050461A YUP-2005/0461A YUP20050461A RS20050461A RS 20050461 A RS20050461 A RS 20050461A YU P20050461 A YUP20050461 A YU P20050461A RS 20050461 A RS20050461 A RS 20050461A
Authority
RS
Serbia
Prior art keywords
formula
compound
inhibitor
pharmaceutically acceptable
cytochrome
Prior art date
Application number
YUP-2005/0461A
Other languages
English (en)
Serbian (sr)
Inventor
Michael Graham Cordingley
Original Assignee
Boehringer Ingelheim International Gmbh.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh., filed Critical Boehringer Ingelheim International Gmbh.,
Publication of RS20050461A publication Critical patent/RS20050461A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
YUP-2005/0461A 2002-12-16 2003-12-15 Primena kombinacije koja obuhvata inhibitor nenukleotidne reverzne transkriptaze (nnrti) sa inhibitorom citohroma p450, kao što su inhibitori proteaze RS20050461A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43369002P 2002-12-16 2002-12-16
PCT/EP2003/014224 WO2004054586A1 (en) 2002-12-16 2003-12-15 Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors

Publications (1)

Publication Number Publication Date
RS20050461A true RS20050461A (sr) 2007-08-03

Family

ID=32595224

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-2005/0461A RS20050461A (sr) 2002-12-16 2003-12-15 Primena kombinacije koja obuhvata inhibitor nenukleotidne reverzne transkriptaze (nnrti) sa inhibitorom citohroma p450, kao što su inhibitori proteaze

Country Status (20)

Country Link
US (2) US20040152625A1 (enExample)
EP (1) EP1575595A1 (enExample)
JP (1) JP2006511538A (enExample)
KR (1) KR20050085681A (enExample)
CN (1) CN1726041A (enExample)
AU (1) AU2003296647A1 (enExample)
BR (1) BR0317095A (enExample)
CA (1) CA2510143A1 (enExample)
EA (1) EA200500894A1 (enExample)
EC (1) ECSP055854A (enExample)
HR (1) HRP20050557A2 (enExample)
IL (1) IL169099A0 (enExample)
MX (1) MXPA05005773A (enExample)
NO (1) NO20053455L (enExample)
NZ (1) NZ541187A (enExample)
PL (1) PL376900A1 (enExample)
RS (1) RS20050461A (enExample)
UA (1) UA81003C2 (enExample)
WO (1) WO2004054586A1 (enExample)
ZA (1) ZA200502947B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US7388008B2 (en) 2004-08-02 2008-06-17 Ambrilia Biopharma Inc. Lysine based compounds
EP1877091B1 (en) * 2005-04-27 2015-03-25 TaiMed Biologics, Inc. Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors
EP1971615B1 (en) 2005-11-30 2014-01-01 TaiMed Biologics, Inc. Lysme-based prodrugs of aspartyl protease inhibitors and processes for their preparation
CN1907138B (zh) * 2006-08-11 2011-01-12 华南师范大学 一种沙田柚子汁提取物及其提取方法和应用
EP2064177B1 (en) 2006-09-21 2017-04-05 TaiMed Biologics, Inc. Protease inhibitors
CA2753382C (en) 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CA2758644C (en) 2009-04-25 2018-01-09 F. Hoffmann-La Roche Ag Methods for improving pharmacokinetics
EP2429568B1 (en) 2009-05-13 2016-08-17 Enanta Pharmaceuticals, Inc. Macrocyclic compounds as hepatitis c virus inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
WO2018041989A1 (en) 2016-09-02 2018-03-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating refractory celiac disease type 2
EP3947737A2 (en) 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020212395A1 (en) 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
US20250283174A1 (en) 2022-05-16 2025-09-11 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stem cells induced by chronic inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
JP2001518899A (ja) * 1997-04-07 2001-10-16 トライアングル ファーマシューティカルズ，インコーポレイティド 他の抗ウイルス剤との組合せにおけるｍｋｃ−４４２の使用
JP2002528502A (ja) * 1998-11-04 2002-09-03 ファルマシア・アンド・アップジョン・カンパニー チプラナビルの薬物動態を改善する方法
US6391919B1 (en) * 2000-01-12 2002-05-21 Bristol-Myers Squibb Pharma Company Bis-amino acid sulfonamides containing substituted benzyl amines HIV protease inhibitors
TWI270547B (en) * 2000-06-16 2007-01-11 Boehringer Ingelheim Ca Ltd Non-nucleoside reverse transcriptase inhibitors
EP1554276B1 (en) * 2002-09-19 2006-06-28 Boehringer Ingelheim (Canada) Ltd. Non-nucleoside reverse transcriptase inhibitors

Also Published As

Publication number Publication date
HRP20050557A2 (en) 2006-05-31
EP1575595A1 (en) 2005-09-21
MXPA05005773A (es) 2005-08-16
NZ541187A (en) 2007-12-21
KR20050085681A (ko) 2005-08-29
US20040152625A1 (en) 2004-08-05
CN1726041A (zh) 2006-01-25
IL169099A0 (en) 2007-07-04
PL376900A1 (pl) 2006-01-09
EA200500894A1 (ru) 2006-02-24
NO20053455L (no) 2005-08-10
CA2510143A1 (en) 2004-07-01
ECSP055854A (es) 2006-01-16
UA81003C2 (en) 2007-11-26
US20080096832A1 (en) 2008-04-24
ZA200502947B (en) 2008-01-30
WO2004054586A1 (en) 2004-07-01
JP2006511538A (ja) 2006-04-06
AU2003296647A1 (en) 2004-07-09
BR0317095A (pt) 2005-10-25

Similar Documents

Publication Publication Date Title
US20080096832A1 (en) Method for Improving the Pharmacokinetics of an NNRTI
US6667329B1 (en) Agents with antidepressant action, containing pramipexol and second antidepressant
JP2010528051A (ja) デング感染症の治療または予防のための抗ウイルス薬
JP2010538000A (ja) アレナウイルス感染症を治療するための抗ウイルス薬
HUP0103922A2 (hu) Pramipexolt és egy további antidepresszánst tartalmazó depresszióellenes hatású szer
CA2664935A1 (en) Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c
JP2003523944A (ja) Ｐ−糖タンパク質修飾物質を用いる抗ウィルス療法
US20060229293A1 (en) Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C
KR930007252B1 (ko) 우울증 치료용 약학조성물
US6498173B1 (en) Synergistic combination comprising roflumilast and a pde-3 inhibitor
TW202106690A (zh) 皮膚型紅斑狼瘡之治療
US20040122068A1 (en) Pramipexole for the treatment of HIV dementia
JPWO2004017973A1 (ja) 統合失調症治療剤
WO2005007191A1 (ja) 医薬組成物
AU2017288456A1 (en) Vortioxetine dosing regimes for fast onset of antidepressant effect
US20240269104A1 (en) Method for treating parkinson's disease
US20080255238A1 (en) Composition containing a thiourea derivative for preventing or treating pruritic or irritant skin diseases
US7842702B2 (en) Treatment for irritable bowel syndrome
JP7257091B2 (ja) 認知症の治療及び予防薬
JPS62267227A (ja) 血中尿酸濃度の低下用医薬
HK1085921A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450, such as protease inhibitors
WO2021242905A1 (en) Concomitant administration of glucocorticoid receptor modulator relacorilant and cyp2c8 substrates
CN120815160A (zh) 一种药物组合物在制备治疗心肌缺血/再灌注损伤药物中的应用
HK40088174A (zh) 排尿症状治疗剂
HK40088174B (zh) 排尿症状治疗剂